ट्रेड Vir Biotechnology VIR

VirBiotechnology लाइव चार्ट

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

VirBiotechnology news

नवीनतम समाचार

और दिखाएं
Euro firms ahead of ECB meeting on June 6
Tommy Yap 2025 Jul 19, 21:00

Week Ahead: Japan Election, ECB Interest Rate Decision, Powell’s Speech

Forex Indices
Ava Grace 2025 Jul 18, 15:20

Market Review: Global Financial Markets Respond to Inflation, Geopolitics

Sophia Claire 2025 Jul 18, 13:20

Fed Governor Waller Urges July Rate Cut Amid Private Sector Concerns

Ava Grace 2025 Jul 18, 12:20

EU Imposes New Sanctions on Russia Targeting Energy and Finance

Emma Rose 2025 Jul 18, 10:20

Escalating Tensions: Israel and Syria Clash Over Druze Minority and Buffer Zone

Liam James 2025 Jul 18, 04:20

Trump Administration to Release Epstein Grand Jury Testimony Amid Mounting Pressure

Emma Rose 2025 Jul 18, 03:20

OpenAI Enters AI Agent Race with ChatGPT Agent Launch

Liam James 2025 Jul 18, 01:20

Warsh Calls for Fed Reform and Policy Alignment with Treasury

जानकारी

स्प्रेड

0.05

स्प्रेड (%)

0.9259 %

लीवरेज

1:10

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

13:31 - 19:59

मंगवार

13:31-19:59

बुधवार

13:31-19:59

गुरुवार

13:31-19:59

शुक्रवार

13:31-19:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

758925568

बकाया शेयर

138238000

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

पूर्व-लाभांश तिथि

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-4.23

इस उपकरण के बारे में अधिक जानें

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें
view_all_instruments

latest_education_articles

और दिखाएं
Trustpilot